Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-58 (Cancelled).

59. (Amended) A method of preparing a purified biologically active alpha 1-antitrypsin (α1-AT) preparation containing an α1- AT isomer having a pI of between 4.3 and 4.4 comprising: providing a starting material containing active and inactive α1- AT, wherein the starting material is a plasma fraction obtained from pooled human plasma; providing a hydroxyapatite substrate; passing said starting material containing α1- AT over said hydroxyapatite substrate; and eluting said purified biologically active alpha 1-antitrypsin (α1-AT) preparation containing an α1- AT isomer having a pI of betwee4.3 and 4.4

60. (Previously presented) The method of preparing a purified biologically active alpha 1-antitrypsin (α1- AT) preparation according to claim 59, further comprising passing said material containing α1- AT over an anion exchange material.

61. (Previously presented) The method according to claim 59, wherein said eluting step is conducted with a buffer having a pH of between 5.5 and 8.0.

62. (Previously presented) The method according to claim 61, wherein said eluting step is conducted with a buffer having a pH of between 6.5 and 6.8.

63. (Cancelled)

64. (Previously presented) The method according to claim 59, wherein said starting material is an albumin-depleted plasma fraction.

65. (Previously presented) The method according to claim 59, wherein said starting material is Cohn V precipitate.

66. (Previously presented) The method according to claim 64, wherein said starting material is a pre-purified α1- AT preparation fraction.

67. (Previously presented) The method according to claim 60, wherein said passing is conducted in the presence of a detergent.

68. (Previously presented) The method according to claim 59, wherein said hydroxyapatite is a ceramic hydroxyapatite.

69. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 60 mM of phosphate.

70. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 40 mM of phosphate.

71. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 50 to 130 mM of phosphate.

72. (Previously presented) The method as set forth in claim 59, further comprising a pathogen inactivation step.

73. (Previously presented) The method as set forth in claim 72, wherein said pathogen inactivation step includes at least one of a solvent, a detergent or a heat treatment step.

74. (new) A method for purifying biologically active alpha1-AT including alpha1-AT isomers having pIs of between 4.3 and 4.4 from an alpha1-AT-containing fraction which is preferably obtainable from a human plasma pool comprising:

Absorbing said acidified alpha1-AT-containing fraction onto a chromatographic anion exchanger in the presence of a detergent, and

Eluting said biologically active alpha1-AT from said chromatographic anion exchanger including alpha1-AT isomers having pIs of between 4.3 and 4.4

74. (new) A method according to claim 74 in which said elution is carried out at a pH ranging between 5.5 and 8.0, preferably around 6.5-6.8